Immunohistochemical expression of CD44s in human neuroblastic tumors: Moroccan experience and highlights on current data

Diagnostic Pathology

Volumn 8, Issue 1, 2013, Pages

  Tabyaoui, Imane ^a   Tahiri Jouti, Nadia ^a   Serhier, Zineb ^a   Bennani Othmani, Mohamed ^a   Sibai, Hicham ^b   Itri, Mohamed ^b   Benchekroun, Said ^b   Zamiati, Soumaya ^a,b  

^a HASSAN II UNIVERSITY   (Morocco)

^b IBN ROCHD UNIVERSITY HOSPITAL   (Morocco)

Author keywords

CD44s; Human; Immunohistochemistry; Metastasis; Moroccan; Peripheral neuroblastic tumors; Prognosis

Indexed keywords

CD44 PROTEIN, HUMAN; FIXATIVE; FORMALDEHYDE; HERMES ANTIGEN; MYCN PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; PARAFFIN; TUMOR MARKER;

ADOLESCENT; ARTICLE; CANCER GRADING; CANCER STAGING; CELL DIFFERENTIATION; CHI SQUARE DISTRIBUTION; CHILD; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GANGLIONEUROMA; GENE AMPLIFICATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; INFANT; MALE; METHODOLOGY; MOROCCO; MULTIVARIATE ANALYSIS; NEUROBLASTOMA; NEWBORN; PATHOLOGY; PRESCHOOL CHILD; PROGNOSIS; RETROSPECTIVE STUDY; STATISTICAL MODEL; TISSUE FIXATION; TUMOR INVASION; UPREGULATION;

ADOLESCENT; ANTIGENS, CD44; CELL DIFFERENTIATION; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; FEMALE; FIXATIVES; FORMALDEHYDE; GANGLIONEUROBLASTOMA; GANGLIONEUROMA; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; INFANT, NEWBORN; LIKELIHOOD FUNCTIONS; LINEAR MODELS; LOGISTIC MODELS; MALE; MOROCCO; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PARAFFIN EMBEDDING; PROGNOSIS; RETROSPECTIVE STUDIES; TISSUE FIXATION; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

MLCS; MLOWN;

EID: 84874718739     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-8-39     Document Type: Article

References (46)

1. Shimada H, Nakagawa A. Pathology of the peripheral neuroblastic tumors. Labmedicine 2006, 37(11):684-689.
2. Lonergan GJ, Schwab CM, Suarez ES, Carlson CL. Neuroblastoma, ganglioneuroblastoma, and ganglioneuroma: radiologic-pathologic correlation. RadioGraphics 2002, 22(4):911-934.
3. Schwab M, Westermann F, Hero B, Berthold F. Neuroblastoma: biology and molecular and chromosomal pathology. Lancet Oncol 2003, 4:472-480. 10.1016/S1470-2045(03)01166-5, 12901961.
4. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B. Terminology and morphologic criteria of neuroblastic tumors. Recommendations by the international Neuroblastoma pathology committee. Cancer 1999, 86:349-363. 10.1002/(SICI)1097-0142(19990715)86:2<349::AID-CNCR20>3.0.CO;2-Y, 10421272.
5. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B, Stram DO, Gerbing RB, Lukens JN, Matthay KK, Castleberry RP. The international Neuroblastoma pathology classification (the Shimada system). Cancer 1999, 86:364-372. 10.1002/(SICI)1097-0142(19990715)86:2<364::AID-CNCR21>3.0.CO;2-7, 10421273.
6. Peuchmaur M, D'Amore ES, Joshi VV, Hata J, Roald B, Dehner LP, Gerbing RB, Stram DO, Lukens JN, Matthay KK, Shimada H. Revision of international Neuroblastoma pathology classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular. Cancer 2003, 98:2274-2281. 10.1002/cncr.11773, 14601099.
7. Peuchmaur M. Les tumeurs neuroblastiques périphériques, classification anatomo-pathologique. Ann Pathol 2004, 24(6):556-567. 10.1016/S0242-6498(04)94018-7, 15785402.
8. Zimling ZG, Rechnitzer C, Rasmussen M, Petersen BL. Peripheral neuroblastic tumours in eastern Denmark 1972-2002. APMIS 2007, 115(1):66-74. 10.1111/j.1600-0463.2007.apm_355.x, 17223852.
9. London WB, Castleberry RP, Matthay KK, Look AT, Seeger RC, Shimada H, Thorner P, Brodeur G, Maris JM, Reynolds CP, Cohn SL. Evidence for an Age cutoff greater than 365 days for Neuroblastoma risk group stratification in the Children's oncology group. J Clin Oncol 2005, 3:6459-6465.
10. George RE, Variend S, Cullinane C, Cotterill SJ, McGuckin AG, Ellershaw C, Lunec J, Pearson ADJ. Relationship between histopathological features, MYCN amplification, and prognosis: a UKCCSG study. Med Pediatr Oncol 2001, 36:169-176. 10.1002/1096-911X(20010101)36:1<169::AID-MPO1041>3.0.CO;2-U, 11464876.
11. Goto S, Umehara S, Gerbing RB, Stram DO, Brodeur GM, Seeger RC, Lukens JN, Matthay KK, Shimada H. Histopathology (international Neuroblastoma pathology classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's cancer group. Cancer 2001, 92(10):2699-2708. 10.1002/1097-0142(20011115)92:10<2699::AID-CNCR1624>3.0.CO;2-A, 11745206.
12. Wang M, Zhou C, Cai R, Li Y, Gong L. Copy number gain of MYCN gene is a recurrent genetic aberration and favorable prognostic factor in Chinese pediatric Neuroblastoma patients. Diagn Pathol 2013, 8:5. 10.1186/1746-1596-8-5, 3567989, 23320395.
13. Brodeur GM, Minturn JE, Ho R, Simpson AM, Iyer R, Varela CR, Light JE, Kolla V, Evans AE. Trk receptor expression and inhibition in neuroblastomas. Clin Cancer Res 2009, 15(10):3244-3250. 10.1158/1078-0432.CCR-08-1815, 19417027.
14. Schneiderman J, London WB, Brodeur GM, Castleberry RP, Look AT, Cohn SL. Clinical significance of MYCN amplification and ploidy in favorable-stage Neuroblastoma: a report from the Children's oncology group. J Clin Oncol 2008, 26(6):913-918. 10.1200/JCO.2007.13.9493, 18281664.
15. Castel V, Grau E, Noguera R, Martínez F. Molecular biology of Neuroblastoma. Clin Transl Oncol 2007, 9:478-483. 10.1007/s12094-007-0091-7, 17720650.
16. Janoueix-Lerosey I, Schleiermacher G, Delattre O. Molecular pathogenesis of peripheral neuroblastic tumors. Oncogene 2010, 29:1566-1579. 10.1038/onc.2009.518, 20101209.
17. Fischer M, Berthold F. The role of complex genomic alterations in Neuroblastoma risk estimation. Genome Medicine 2010, 2:31-34. 10.1186/gm152, 2887075, 20497596.
18. Goodison S, Urquidi V, Tarin D. CD44 Cell adhesion molecules. J Clin Pathol: Mol Pathol 1999, 52:189-196.
19. Necas J, Bartosikova L, Brauner P, Kolar J. Hyaluronic acid (hyaluronan): a review. Vet Med-CZECH 2008, 53(8):397-411.
20. Sneath RJS, Mangham DC. The normal structure and function of CD44 and its role in neoplasia. J Clin Pathol: Mol Pathol 1998, 51:191-200.
21. Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Bio 2003, 4:33-45.
22. Orian-Rousseau V. CD44, un régulateur de la croissance et de l'invasion cellulaire. Med Sci 2003, 19(4):405-407.
23. Rudzki Z, Jothy S. CD44 And the adhesion of neoplastic cells. J Clin Pathol: Mol Pathol 1997, 50:57-71.
24. Moudouni S, En-nia I, Rioux-Leclerq N, Bensalah K, Guille F, Lobel B. Le carcinome à cellules claires du rein avant 40 ans: facteurs pronostiques. Prog Urol 2002, 12:575-578.
25. Liu J, Jiang G. CD44 And hematologic malignancies. Cell Mol Immunol 2006, 3:359-365.
26. Hertweck MK, Erdfelder F, Kreuzer KA. CD44 In hematological neoplasias. Ann Hematol 2011, 90(5):493-508. 10.1007/s00277-011-1161-z, 21258793.
27. Noordzij MA, Van Steenbrugge GJ, Verkaik NS, Schroder FH, Van Der Kwast TH. The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy. Clin Cancer Res 1997, 3:805-815.
28. Combaret V, Gross N, Lasset C, Frappaz D, Beretta-Brognara C, Philip T, Beck D, Favrot MC. Clinical relevance of CD44 cell surface expression and MYCN gene amplification in Neuroblastoma. Eur J Cancer 1997, 33(12):2101-2105. 10.1016/S0959-8049(97)00236-0, 9516862.
29. Papaioannou G, Mchugh K. Neuroblastoma in childhood: review and radiological findings. Cancer Imaging 2005, 5:116-127. 10.1102/1470-7330.2005.0104, 1665241, 16305949.
30. Taran K, Kobos J, Sitkiewicz A, Sporny S. Estimation of prognostic value of CD44 expression in neuroblastic tumours in children. Folia Neuropathol 2007, 45(3):126-132.
31. Combaret V, Lasset C, Frappaz D, Bouvier R, Thiesse P, Rebillard AC, Philip T, Favrot MC. Evaluation of CD44 prognostic value in Neuroblastoma: comparison with the other prognostic factors. Eur J Cancer 1995, 31A(4):545-549.
32. Combaret V, Gross N, Lasset C, Frappaz D, Peruisseau G, Philip T, Beck D, Favrot MC. Clinical relevance of CD44 cell-surface expression and N-myc gene amplification in a multicentric analysis of 121 pediatric neuroblastomas. J Clin Oncol 1996, 14(1):25-34.
33. Christiansen H, Sahin K, Berthold F, Hero B, Terpe HJ, Lampert F. Comparison of DNA aneuploidy, chromosome 1 abnormalities, MYCN amplification and CD44 expression as prognostic factors in Neuroblastoma. Eur J Cancer 1995, 31A(4):541-544.
34. Gross N, Beretta C, Peruisseau G, Jackson D, Simmons D, Beck D. CD44H Expression by human Neuroblastoma cells: relation to MYCN amplification and lineage differentiation. Cancer Res 1994, 54(15):4238-4242.
35. Terpe HJ, Christiansen H, Gonzalez M, Berthold F, Lampert F. Differentiation and prognosis of Neuroblastoma in correlation to the expression of CD44s. Eur J Cancer 1995, 31A(4):549-552.
36. Hasegawa G, Minami N, Kushida A, Inuyama H, Koga M, Wakabayashi K, Saito Y. Human Neuroblastoma GOTO cells express CD44 and localize it into lipid rafts upon differentiation into schwannian cells. Cell Biol Int 2005, 29(3):193-202. 10.1016/j.cellbi.2004.09.011, 15878294.
37. Munchar MJ, Sharifah NA, Jamal R, Looi LM. CD44s Expression correlated with the international Neuroblastoma pathology classification (Shimada system) for neuroblastic tumours. Pathology 2003, 35(2):125-129.
38. Marhaba R, Zöller M. CD44 In cancer progression: adhesion, migration and growth regulation. J Mol Histol 2004, 35(3):211-231.
39. Yoon KJ, Danks MK. Cell adhesion molecules as targets for therapy of Neuroblastoma. Cancer Biol Ther 2009, 8(4):306-311. 10.4161/cbt.8.4.7446, 19197150.
40. Kendziorra H, Kumpf M, Mackensen-Haen S, Bültmann B. Hypertrophic obstructive cardiomyopathy of an infant with Neuroblastoma: a case report. Diagn Pathol 2007, 2(Suppl 1):S20.
41. Zöller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?. Nat Rev Cancer 2011, 11(4):254-267. 10.1038/nrc3023, 21390059.
42. Sugino T, Gorham H, Yoshida K, Bolodeoku J, Nargund V, Cranston D, Goodison S, Tarin D. Progressive loss of CD44 gene expression in invasive bladder cancer. Am J Pathol 1996, 149(3):873-882. 1865145, 8780391.
43. Stavropoulos NE, Filliadis I, Ioachim E, Michael M, Mermiga E, Hastazeris K, Nseyo UO. CD44 Standard form expression as a predictor of progression in high risk superficial bladder tumors. Int Urol Nephrol 2001, 33(3):479-483. 10.1023/A:1019589923706, 12230276.
44. Valentiner U, Valentiner FU, Schumacher U. Expression of CD44 is associated with a metastatic pattern of human Neuroblastoma cells in a SCID mouse xenograft model. Tumour Biol 2008, 29(3):152-160. 10.1159/000143401, 18612220.
45. Siapati EK, Rouka E, Kyriakou D, Vassilopoulos G. Neuroblastoma cells negative for CD44 possess tumor-initiating properties. Cell Oncol 2011, 34(3):189-197.
46. Blaheta RA, Hundemer M, Mayer G, Vogel JU, Kornhuber B, Cinatl J, Markus BH, Driever PH, Cinatl J. Expression level of neural cell adhesion molecule (NCAM) inversely correlates with the ability of Neuroblastoma cells to adhere to endothelium in vitro. Cell Commun Adhes 2002, 9:131-147. 10.1080/15419060214520, 12521134.